Test Price
900 AED✅ Home Collection Available
AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test in Dubai | 900 AED | Accurate MRD Monitoring
Executive Summary & Core Metrics
- Diagnostic Sensitivity: 99.9% via ISO-certified molecular processing and quality controls.
- Sample Type: Bone Marrow Aspirate or Peripheral Blood (hospital-extraction only — no home phlebotomy available for this invasive procedure).
- Turnaround Time: 48–72 hours from sample receipt to secure digital report.
- Clinical Guidance: Post-test telephonic consultation by a DHA-licensed genetics specialist included at no extra cost.
- Insurance: Direct coverage verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The AML ETO t(8;21) PCR qualitative test detects the RUNX1-RUNX1T1 fusion transcript with a limit of detection of 0.001%, enabling early diagnosis and minimal residual disease (MRD) monitoring in acute myeloid leukemia. It is the gold‑standard molecular assay for core‑binding factor AML, performed exclusively in ISO‑certified laboratories under DHA regulatory oversight. Real‑time PCR is supplemented by NGS confirmation for definitive risk stratification.
| Feature | Our Test (Real‑Time PCR + NGS Confirmation) | Closest Alternative (FISH / Cytogenetics) |
|---|---|---|
| Methodology | qPCR (RQ‑PCR) with NGS confirmation; detects fusion transcript at mRNA level | Fluorescence in‑situ hybridization (FISH); DNA‑level detection only |
| Analytical Sensitivity | 0.001% (1 leukemic cell in 100,000 normal cells) | ~0.5–1% (limited by probe cross‑hybridization) |
| Turnaround Time | 48–72 hours (sample receipt to report) | 5–7 working days |
| MRD Monitoring Utility | Excellent – quantitative and qualitative follow‑up | Not suitable for MRD |
Physician Insight & Safety Protocols
“The AML ETO t(8;21) rearrangement is a sentinel molecular marker that must be correlated with bone marrow morphology and flow cytometry. A positive result in an asymptomatic individual does not equate to active leukemia; it requires immediate hematology consultation to rule out clonal hematopoiesis of indeterminate potential (CHIP). – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403”
Advisory: Medication & Clinical Precautions
Patients should not discontinue any prescribed therapy without prior discussion with their treating hematologist. Certain medications may interact with test interpretation or require dose adjustments during MRD monitoring. Always provide a complete list of current medications to the laboratory at the time of sample collection.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria:
- Age below 18 years without guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Active uncontrolled infection or febrile neutropenia.
- Recent bone marrow transplant (< 3 months) may produce ambiguous results.
- Pregnancy – not contraindicated but requires multidisciplinary approval.
ER Red Flags – Seek Immediate Care:
- Fever >38.3°C with chills.
- Unexplained bruising, petechiae, or active bleeding.
- Severe bone pain or sudden visual changes.
- Respiratory distress or new neurological symptoms.
Patient FAQ & Clinical Guidance
1. What is the purpose of the AML ETO t(8;21) qualitative PCR test?
This molecular test detects the RUNX1-RUNX1T1 fusion transcript, the hallmark of core-binding factor acute myeloid leukemia (AML). It confirms the specific genetic rearrangement, stratifies patients into a favorable risk group, and enables ultra-sensitive monitoring of minimal residual disease (MRD) to detect impending relapse before clinical signs appear. A negative result effectively rules out active t(8;21)-positive disease.
2. How should I prepare for this test?
No special preparation (fasting or medication adjustment) is required. However, because the sample must be obtained via bone marrow aspiration or venipuncture in a hospital setting, you will be scheduled at an accredited facility. Please inform your referring physician of any anticoagulant or antiplatelet use beforehand.
3. How is the sample collected and transported?
A bone marrow aspirate or peripheral blood sample (3 mL in EDTA) is collected by a qualified professional at a hospital. The specimen is immediately refrigerated and transported via temperature‑controlled cold chain to our ISO‑certified laboratory. Mobile home phlebotomy is not available for this procedure due to the invasive nature of sample acquisition.
4. When can I expect my results?
Reports are issued within 48–72 hours of sample receipt. You will receive a secure digital report together with a telephonic clinical interpretation from a DHA‑licensed genetics specialist who will explain the findings in plain language and discuss next steps.
UAE Regulatory & Data Privacy Adherence
Compliance & Accreditation
This diagnostic service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our facility operates under DHA Facility License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate identity: DNA Labs UAE. All patient data are encrypted, processed in ISO 9001:2015 certified environments (Cert: INT/EGQ/2509DA/3139), and never shared with third parties without explicit written consent.
Clinical & Logistical Metadata
| Test Name | AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test |
| Price (AED) | 900 |
| Turnaround Time | 48–72 hours from sample receipt |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood (Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.) |
| Methodology Used | Qualitative Real-Time PCR (qPCR) with NGS confirmation |
| ICD-10-CM Code | C92.5 (Acute myeloid leukemia with t(8;21)(q22;q22); AML1-ETO) |
| LOINC Code | 49908-2 (RUNX1-RUNX1T1 fusion transcript) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians